Literature DB >> 24488068

Rebuttal from Marc Pourrier, Sarah Williams, Donald McAfee, Luiz Belardinelli and David Fedida.

Marc Pourrier1, Sarah Williams, Donald McAfee, Luiz Belardinelli, David Fedida.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24488068      PMCID： PMC3930424          DOI： 10.1113/jphysiol.2013.268896

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  10 in total

Review 1.  Pathophysiology and pharmacology of the cardiac "late sodium current.".

Authors:  Antonio Zaza; Luiz Belardinelli; John C Shryock
Journal:  Pharmacol Ther       Date:  2008-07-01       Impact factor: 12.310

2.  CrossTalk opposing view: the late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction).

Authors:  Zoltán Papp; Attila Borbély; Walter J Paulus
Journal:  J Physiol       Date:  2014-02-01       Impact factor: 5.182

3.  Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium.

Authors:  Samuel Sossalla; Nina Fluschnik; Hanna Schotola; Katharina R Ort; Stefan Neef; Timo Schulte; Katrin Wittköpper; André Renner; Jan D Schmitto; Jan Gummert; Ali El-Armouche; Gerd Hasenfuss; Lars S Maier
Journal:  Circ Res       Date:  2010-09-02       Impact factor: 17.367

4.  Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Lina Yao; Peidong Fan; Martina Del Lungo; Francesca Stillitano; Laura Sartiani; Benedetta Tosi; Silvia Suffredini; Chiara Tesi; Magdi Yacoub; Iacopo Olivotto; Luiz Belardinelli; Corrado Poggesi; Elisabetta Cerbai; Alessandro Mugelli
Journal:  Circulation       Date:  2012-12-27       Impact factor: 29.690

5.  A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.

Authors:  Luiz Belardinelli; Gongxin Liu; Cathy Smith-Maxwell; Wei-Qun Wang; Nesrine El-Bizri; Ryoko Hirakawa; Serge Karpinski; Cindy Hong Li; Lufei Hu; Xiao-Jun Li; William Crumb; Lin Wu; Dmitry Koltun; Jeff Zablocki; Lina Yao; Arvinder K Dhalla; Sridharan Rajamani; John C Shryock
Journal:  J Pharmacol Exp Ther       Date:  2012-09-25       Impact factor: 4.030

6.  Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure.

Authors:  Nidas A Undrovinas; Victor A Maltsev; Luiz Belardinelli; Hani N Sabbah; Albertas Undrovinas
Journal:  J Physiol Sci       Date:  2010-05-19       Impact factor: 2.781

7.  Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels.

Authors:  Stefan Wagner; Nataliya Dybkova; Eva C L Rasenack; Claudius Jacobshagen; Larissa Fabritz; Paulus Kirchhof; Sebastian K G Maier; Tong Zhang; Gerd Hasenfuss; Joan Heller Brown; Donald M Bers; Lars S Maier
Journal:  J Clin Invest       Date:  2006-11-22       Impact factor: 14.808

8.  Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.

Authors:  Arthur J Moss; Wojciech Zareba; Karl Q Schwarz; Spencer Rosero; Scott McNitt; Jennifer L Robinson
Journal:  J Cardiovasc Electrophysiol       Date:  2008-07-25

9.  Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.

Authors:  Samuel Sossalla; Stefan Wagner; Eva C L Rasenack; Hanna Ruff; Sarah L Weber; Friedrich A Schöndube; Theodor Tirilomis; Gero Tenderich; Gerd Hasenfuss; Luiz Belardinelli; Lars S Maier
Journal:  J Mol Cell Cardiol       Date:  2008-03-14       Impact factor: 5.000

10.  RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

Authors:  Lars S Maier; Beth Layug; Ewa Karwatowska-Prokopczuk; Luiz Belardinelli; Stella Lee; Julia Sander; Christian Lang; Rolf Wachter; Frank Edelmann; Gerd Hasenfuss; Claudius Jacobshagen
Journal:  JACC Heart Fail       Date:  2013-04-01       Impact factor: 12.035
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.